Hostname: page-component-cb9f654ff-rkzlw Total loading time: 0 Render date: 2025-08-27T22:50:57.434Z Has data issue: false hasContentIssue false
  • English
  • Français

The NIMH MATRICS Initiative: Development of a Consensus Cognitive Battery

Published online by Cambridge University Press:  05 October 2006

Robert S. Kern ,
Michael F. Green  and
Stephen R. Marder
Robert S. Kern
Affiliation:
Department of Psychiatry and Biobehavioral Sciences, Geffen School of Medicine at UCLA, Department of Veterans Affairs VISN 22 Mental Illness Research, Education, and Clinical Center, Los Angeles, California, USA; Email:rkern@ucla.edu; mgreen@ucla.edu; marder@ucla.edu
Michael F. Green
Affiliation:
Department of Psychiatry and Biobehavioral Sciences, Geffen School of Medicine at UCLA, Department of Veterans Affairs VISN 22 Mental Illness Research, Education, and Clinical Center, Los Angeles, California, USA; Email:rkern@ucla.edu; mgreen@ucla.edu; marder@ucla.edu
Stephen R. Marder
Affiliation:
Department of Psychiatry and Biobehavioral Sciences, Geffen School of Medicine at UCLA, Department of Veterans Affairs VISN 22 Mental Illness Research, Education, and Clinical Center, Los Angeles, California, USA; Email:rkern@ucla.edu; mgreen@ucla.edu; marder@ucla.edu
Get access Rights & Permissions [Opens in a new window]

Extract

ABSTRACT

A key obstacle to the development of new drugs to treat the cognitive deficits of schizophrenia was the absence of a standard by which to measure their efficacy. Before granting approval for any new drug for this condition, the US Food and Drug Administration wanted a standard cognitive endpoint based on a broad consensus-based method. To address this obstacle, the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) intiative oversaw a process to develop a consensus neurocognitive battery. Its development included a ten-step process that is described in this article.

Keywords

cognitionschizophreniatests and measurement

Information

Type
Review Article
Information
Progress in Neurotherapeutics and Neuropsychopharmacology , Volume 2 , Issue 1 , March 2007 , pp. 173 - 186
Copyright
© 2007 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Bilder, R.M., Goldman, R.S., Robinson, D., Reiter, G., Bell, L., Bates, J.A., et al. (2000). Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. American Journal of Psychiatry, 157, 549–559.CrossRefGoogle Scholar
Bilder, R.M., Goldman, R.S., Volavka, J., Czobor, P., Hoptman, M., Sheitman, B., Lindenmayer, J.P., Citrome, L., McEvoy, J., Kunz, M., Chakos, M., Cooper, T.B., Horowitz, T.L., & Lieberman, J.A. (2002). Neurocognitive effects of clozapine,olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. American Journal of Psychiatry, 159, 1018–1028.CrossRefGoogle Scholar
Buchanan, R.W., Davis, M., Goff, D., Green, M.F., Keefe, R.S., Leon, A.C., Nuechterlein, K.H., Laughren, T., Levin, R., Stover, E., Fenton, W., & Marder, S.R. (2005). A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophrenia Bulletin, 31, 5–19.CrossRefGoogle Scholar
Cornblatt, B., Lenzenweger, M.F., Dworkin, R., & Erlenmeyer-Kimling, L. (1992). Childhood attentional dysfunction predicts social deficits in unaffected adults at risk for schizophrenia. British Journal of Psychiatry, 161, 59–64.Google Scholar
Fernandez-Ruiz, J., Doudet, D., & Aigner, T.G. (1999). Spatial memory improvement by levodopa in parkinsonian MPTP-treated monkeys. Psychopharmacology, 147, 104–107.CrossRefGoogle Scholar
Fitch, K., Bernstein, S.J., Aguilar, M.D., Burnand, B., LaCalle J.R., Lazaro, P., van het Loo, M., McDonnell, J., Vader, J.P., & Kahan J.P. (2001). The RAND/UCLA Appropriateness Method User’s Manual. Santa Monica, California: RAND.
Goff, D.C., Herz, L., Posever, T., Shih, V., Tsai, G., Henderson, D.C., Freudenreich, O., Evins, A.E., Yovel, I., Zhang, H., & Schoenfeld, D.A. (2005). A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology, 179, 144–150.CrossRefGoogle Scholar
Goff, D.C., Tsai, G., Levitt, J., Amico, E., Manoach, D., Schoenfeld, D.A., Hayden, D.L., McCarley, R., & Coyle, J.T. (1999). A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Archives of General Psychiatry, 56, 21–27.CrossRefGoogle Scholar
Gold, J.M. (2004). Cognitive deficits as treatment targets in schizophrenia. Schizophrenia Research, 72, 21–28.CrossRefGoogle Scholar
Goldman-Rakic, P.S., Castner, S.A., Svensson, T.H., Siever, L.J., & Williams, G.V. (2004). Targeting the dopamine D1 receptior in schizophrenia: insights for cognitive dysfunction. Psychopharmacology, 174, 3–16.Google Scholar
Green, M.F. (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry, 153, 321–330.Google Scholar
Green, M.F., & Nuechterlein, K.H. (2004). The MATRICS initiative:developing a consensus cognitive battery for clinical trials. Schizophrenia Research, 72, 1–3.Google Scholar
Green, M.F., Kern, R.S., & Heaton, R.K. (2004). Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophrenia Research, 72, 41–51.CrossRefGoogle Scholar
Green, M.F., Kern, R.S., Braff, D.L., & Mintz, J. (2000). Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the “right stuff”? Schizophrenia Bulletin, 26, 119–136.Google Scholar
Green, M.F., Marder, S.R., Glynn, S.M., McGurk, S.R., Wirshing, W.C., Wirshing, D.A., Liberman, R.P., & Mintz, J. (2002). The neurocognitive effectts of low-dose haloperidol:a two-year comparison with risperidone. Biological Psychiatry, 51, 972–978.CrossRefGoogle Scholar
Green, M.F., Nuechterlein, K.H., Gold, J.M., Barch, D., Cohen, J., Essock, S., Fenton, W.S., Frese, F., Goldberg, T.E., Heaton, R.K., Keefe, R.S.E., Kern, R.S., Kraemer, H., Stover, E., Weinberger, D.R., Zalcman, S., & Marder, S.R. (2004). Approaching a consensus cognitive battery for clinical trials in schizophrenia: TheNIMH-MATRICS conference to select cognitive domains and test criteria. Biological Psychiatry, 56, 301–307.CrossRefGoogle Scholar
Hampson, R.E., Rogers, G., Lynch, G., & Deadwyler, S. (1998). Facilitative effects of the Ampakine CX516 on short term memory in rats: correlations with hippocampal neuronal activity. Journal of Neuroscience, 18, 2748–2763.CrossRefGoogle Scholar
Harvey, P.D., & Keefe, R.S.E. (2001). Studies of the cognitive change in patients with schizophrenia following novel antipsychotic treatment. American Journal of Psychiatry, 158, 176–184.CrossRefGoogle Scholar
Heinrichs, R.W., & Zakzanis, K.K. (1998). Neurocognitive deficit in schizophrenia:a quantitative review of the evidence. Neuropsychology, 12, 426–445.CrossRefGoogle Scholar
Heydebrand, G., Weiser, M., Rabinowitz, J., Hoff, A.L., DeLisi, L.E., & Csernansky, J.G. (2004). Correlates of cognitive deficits in first episode schizophrenia. Schizophrenia Research, 68, 1–9.CrossRefGoogle Scholar
Keefe, R.S.E., Silva, S.G., Perkins, D.O., Lieberman, J.A. (1999). The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophrenia Bulletin, 25, 201–222.CrossRefGoogle Scholar
Kern, R.S., Green, M.F., Nuechterlein, K.H., & Deng, B.-H. (2004). NIMH-MATRICS survey on assessment of neurocognition in schizophrenia. Schizophrenia Research, 72, 11–19.CrossRefGoogle Scholar
Marder, S.R. (2006). The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia. Dialogues in Clinical Neuroscience, 8, 109–113.Google Scholar
Marder, S.R., & Fenton, W. (2004). Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophrenia Research, 72, 5–9.CrossRefGoogle Scholar
Mishara, A.L., & Goldberg, T.E. (2004). A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biological Psychiatry, 55, 1013–1022.CrossRefGoogle Scholar
Mohamed, S., Paulsen, J.S., O’Leary, D.S., Arndt, S., and Andreasen, N.C. (1999). Generalized cognitive deficits in schizophrenia. American Journal of Psychiatry, 156, 749–754.CrossRefGoogle Scholar
Nieuwenstein, M.R., Aleman, A., & de Haan, E.H.F. (2001). Relationship between symptom dimensions and neurocognitive functioning in schizophrenia: a meta-analysis of WCST and CPT studies. Journal of Psychiatric Research, 35, 119–125.CrossRefGoogle Scholar
Nuechterlein, K.H., Asarnow, R.F., Subotnik, K.L., Fogelson, D.L., Ventura, J., Torquato, R., et al. (1998). Neurocognitive vulnerability factors for schizophrenia: convergence across genetic risk studies and longitudinal trait/state studies. In: Lenzenweger, M.F. & Dworkin, R.H.(ed.), Origins and Development of Schizophrenia: Advances in Experimental Psychopathology. Washington, DC: American Psychological Association, pp. 299–327.CrossRef
Nuechterlein, K.H., Barch, D.M., Gold, J.M., Goldberg, T.E., Green, M.F., & Heaton, R.K. (2004). Identification of separable cognitive factors in schizophrenia. Schizophrenia Research, 72, 29–39.CrossRefGoogle Scholar
Palmer, B.W., Appelbaum, M.I., & Heaton, R.K. (2004). Rohling's interpretive method and inherent limitations on the flexibility of “flexible batteries.” Neuropsychology Review, 14, 171–176.CrossRefGoogle Scholar
Palmer, B.W., Heaton, R.K., Paulsen, J.S., Kuck, J., Braff, D., Harris, M.J., et al. (1997). Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology, 11, 437–446.Google Scholar
Perlick, D., Stastny, P., Katz, I., Mayer, M., & Mattis, S. (1986). Memory deficits and anticholinergic levels in chronic schizophrenia. American Journal of Psychiatry, 143, 230–232.Google Scholar
Saykin, A.J., Gur, R.E., Gur, R.C., & Mozley, P.D. (1991). Neuropsychological functionin schizophrenia: selective impairment in memory and learning. Archives of General Psychiatry, 48, 618–622.CrossRefGoogle Scholar
Schneider, J.S., Sun, Z.Q., & Roeltgen, D.P. (1994). Effects of dopamine agonists on delayed response performance in chronic low-dose MPTP-treated monkeys. Pharmacology Biochemistry and Behavior, 48, 235–240.CrossRefGoogle Scholar
Staubli, U., Rogers, G., & Lynch, G. (1994). Facilitation of glutamate receptors enhances memory. Proceedings of the National Academy of Sciences, USA, 91, 777–781.CrossRef
Tulsky, D.S., & Price, L.R. (2003). The joint WAIS-III and WMS-III factor structure: development and cross-validation of a six-factor model of cognitive functioning. Psychological Assessment, 15, 149–162.CrossRefGoogle Scholar
Tune, L.E., Strauss, M.E., Lew, M.F., Breitlinger, E., & Coyle, J.T. (1982). Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. American Journal of Psychiatry, 139, 187–190.Google Scholar
Williams, G.V., & Goldman-Rakic, P.S. (1995). Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature, 376, 549–550.Google Scholar
Woodward, N.D., Purdon, S.E., Meltzer, H.Y., & Zald, D.H. (2005). A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. International Journal of Neuropsychopharmacology, 8, 457–472.CrossRefGoogle Scholar